Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo could supercharge liver cancer radiation

NCT ID NCT07312292

Disease control Sponsor: Niek Wijnen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a short infusion of angiotensin II, given directly into the liver artery, can help radioactive beads reach liver tumors more effectively while sparing healthy tissue. About 15 adults with liver cancer will receive the drug right before standard radioembolization. Researchers will compare scans to see if the drug improves targeting and check for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Patients diagnosed with primary or metastatic liver tumors (any histological type). * A clinical indication for radioembolization. * Liver tumors with a diameter ≥ 2 cm. * Age ≥ 18 years. * Competent and able to provide own informed consent (no legally designated representative). * Written informed consent. Exclusion criteria: * Any serious comorbidity preventing the safe administration of angiotensin II (AT-II). This includes: 1. Uncontrolled hypertension. 2. Treatment with ≥ 3 antihypertensive drugs. 3. Arterial (cerebro-)vascular or venous thromboembolic event within the past 6 months. * Current use of angiotensin-converting enzyme (ACE) inhibitors. * Current use of angiotensin II receptor blockers (ARBs). * Known hypercoagulable state (i.e., thrombophilia). * History of severe peripheral vascular disease. * Known hypersensitivity to the active substance in Giapreza: angiotensin II. * Known hypersensitivity to any of the excipients in Giapreza: mannitol, sodium hydroxide or hydrochloric acid. * Any serious and/or chronic liver disease preventing the safe administration of radioembolization. * Uncorrectable extrahepatic deposition of scout dose activity; activity in the falciform ligament, portal lymph nodes, and gallbladder is accepted. * Pregnancy or breastfeeding. * Body weight over 150 kg (because of maximum table load). * Known severe allergy to intravenous contrast fluids. * Participation in another investigational study which may compromise any endpoint of the study. * Any other significant comorbidity or medical condition that may compromise the safety of radioembolization.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver cancer (locally advanced or metastatic) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver cancer Liver Neoplasms Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cancer (locally advanced or metastatic) Liver cancer, adult

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Medical Center Utrecht

    RECRUITING

    Utrecht, Utrecht, 3584 CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.